乌司他丁在急性呼吸窘迫综合征患者救治中的临床应用

Ulinastatin Treatment for Patients with Acute Respiratory Distress Syn-drome in Clinical Application

目的探讨急性呼吸窘迫综合征(ARDS)患者救治中乌司他丁的临床应用价值。方法整群选取该院ICU于2013年7月—2016年3月收治的ARDS患者共81例,采用双盲法进行分组,其中40例给予常规治疗(对照组),另41例给予乌司他丁治疗(观察组);比较两组血气分析结果、呼吸频率、平均动脉压、心率等,并统计对比两组死亡率。结果治疗前两组各项指标无差异,且差异无统计学意义(P>0.05),治疗后两组均较治疗前存在显著改善,差异具有统计学意义(P<0.05),且治疗后观察组氧分压、血氧饱和度、呼吸频率、心率等指标分别为(98.6±9.7)mm Hg、(97.4±3.4)%、(18.5±3.4)次/min、(76.5±9.4)次/min,显著优于对照组(74.5±6.9)mm Hg、(78.5±4.2)%、(21.8±2.8)次/min、(87.8±9.7)次/min,差异存在统计学意义(P<0.05);观察组死亡4(9.75%),对照组死亡13(32.5%),差异统计学意义(P<0.05)。结论急性呼吸窘迫综合征患者救治中,乌司他丁临床疗效显著,可大幅降低死亡率,值得推广。

Objective To investigate the treatment for patients with acute respiratory distress syndrome（ARDS） in the clinical application value of ulinastatin. Methods Selection atotal of 81 patients with ARDS, double-blind method to group, 40 cases given routine therapy（control group）, the ulinastatin treatment of 41 patients（observation group）; Compare two groups of blood gas analysis, respiratory frequency, mean arterial pressure, heart rate, etc., and statistical compared two groups of mortality. Results Before treatment showed no difference between the two groups is not statistically significant（P〉0.05）,there was a significant improvement in both groups before treatment after treatment was statistically significant（P〈0.05）,and the observation group after treatment oxygen partial pressure, oxygen saturation, respiratory rate, heart rate and other indicators were（98.6 ±9.7）mmHg、（97.4 ±3.4）% 、（18.5 ±3.4）times/min、（76.5 ±9.4）times/min, significantly better than the control group（74.5 ±6.9）mmHg、（78.5 ±4.2）% 、（21.8 ±2.8）times/min、（87.8 ±9.7）times/min, statistically significant differences（P〈0.05）; the observation group died 4（9.75%）, and 13 died in the control group（32.5%）, the difference was statistically significant（P〈0.05）.Conclusion The treatment of patients with acute respiratory distress syndrome, ulinastatin clinical curative effect significantly, can significantly reduce the mortality rate, worthy of promotion.